Alembic Pharma gets EIR for Karakhadi facility
New Delhi: Drug firm Alembic Pharmaceuticals said it has received establishment inspection report (EIR) from the US health regulator for its Karakhadi facility in Gujarat.
The company has received EIR from the United States Food and Drug Administration (USFDA) for the inspection carried out at the active pharmaceutical ingredient facility at Karakhadi from May 14-18, 2018, Alembic Pharmaceuticals said in a BSE filing.
"With this, all our manufacturing facilities for international markets are FDA compliant," it added.
An establishment inspection report is given by the US health regulator USFDA on the closure of inspection of an establishment.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd